|
| On-Demand Webinar: Clinical Adjudication Survey Results Revealed In a recent survey, 89% of clinical adjudication users agreed clinical adjudication provides value to clinical trials. Why? Because using unbiased experts to evaluate a drug or device against predetermined criteria helps determine patient safety and clinical efficacy. Join two experts for a discussion of these and other survey results to understand how they could impact your studies. View Now. |
Stryker ponies up $3B to buy Vocera and amp up its digital communications Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter? AMA pans CDC's 'confusing' COVID-19 isolation guidance, calls for negative test requirement Pfizer, Roche, AstraZeneca and J&J face newly revived lawsuit claiming they funded terrorism in Iraq With Alnylam in rear view, Maraganore wants to be a biotech multiplier, matchmaker and mentor Verily links up with Sosei Heptares for GPCR drug discovery Babylon Health acquires health kiosk company Higi Health in latest effort to scale in U.S. market Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs With dual approvals, Biohaven's migraine blockbuster-in-waiting snares nearly $500M in 2021 Abbott unveils Lingo line of sports biosensors based on diabetes monitoring tech Vera Whole Health to merge with healthcare navigation company Castlight Health in $370M deal Aligos says stop right now to lead hep B med after fruitless phase 1 data Featured Story | By Conor Hale Stryker inked a $3 billion deal to dramatically reshape its digital patient outreach efforts with the acquisition of Vocera Communications. read more |
| |
|---|
|
|
| Webinar: A Collaborative Approach to Complex Chemistry Wednesday, January 12, 2022 | 11am ET / 8am PT Complex therapeutics demand complex chemistry expertise. Discover how the right partner can help you overcome complex chemistry challenges through extensive experience, specialised technologies, and true scientific collaboration. Register now. |
Top Stories By Angus Liu Amid its sputtering launch, Biogen expects to receive a draft decision on Aduhelm’s coverage on Medicare next week. Industry watchers have been calculating a range of potential scenarios, but whichever direction the ruling goes, doctor feedback suggests it may simply not matter that much. read more By Dave Muoio "Physicians are concerned that these recommendations put our patients at risk and could further overwhelm our health care system," wrote AMA President Gerald Harmon, M.D. read more By Kevin Dunleavy Pharmaceutical giants Pfizer, AstraZeneca, Roche and Johnson & Johnson will have to answer to charges that they paid bribes to win healthcare contracts in Iraq and in the process funded terrorists who killed Americans during the war. This week, a U.S. appeals court revived a lawsuit that was filed in 2017 and dismissed three years later. read more By Annalee Armstrong After 19 years at the helm of Alnylam, John Maraganore, Ph.D., is not wasting any time getting started on the next phase of his career. read more By Andrea Park Verily and Sosei Heptares are hitching their wagons to the rising star of G-protein-coupled receptors to develop new drugs for immune-based disorders. read more By Rebecca Torrence Digital health unicorn Babylon Health has acquired health kiosk company Higi Health, the company's latest effort to expand its U.S. footprint by adding RPM tech to its portfolio. read more By Annalee Armstrong Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion biobucks deal to initially create five programs across several diseases. read more By Fraiser Kansteiner Armed with dual approvals in migraine treatment and prevention, Biohaven Pharmaceuticals’ blockbuster-in-waiting Nurtec ODT continued to roll in 2021, ginning up nearly $500 million in revenue. read more By Andrea Park In a keynote address at the annual CES conference, Abbott CEO Robert Ford introduced Lingo, a new line of consumer biowearable sensors. read more By Rebecca Torrence Advanced primary care provider Vera Whole Health is combining with healthcare navigation platform Castlight Health, and will pay $370 million in cash for its shares. News of the deal sent Castlight's stock soaring on Wednesday. read more By Annalee Armstrong Aligos went public back in October 2020, with $40 million of its overall haul going toward its hepatitis B antiviral “STOPS” medicine. But now, what’s stopping is the drug’s development. read more |
